ライフサイエンスコーパス: rhGH

1 rhGH enhances FFM through the stimulation of protein syn

2 rhGH improves whole-body protein homeostasis in chronic

3 rhGH increased FFM and nonoxidative leucine disposal (NO

4 rhGH increased glutamine de novo synthesis (P < 0.02) an

5 y adequate nutritional support with adjuvant rhGH during the postinjury period demonstrates the benef

6 These salutary effects continued after rhGH treatment was discontinued.

7 nt, and IGF-1 concentrations persisted after rhGH treatment (P < 0.05).

8 enous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements

9 creased muscle protein synthesis with PN and rhGH administration is not associated with increased mus

10 petite stimulants and such growth factors as rhGH and rhIGF-I are still in the experimental stage.

11 down was not significantly different between rhGH and placebo (P = 0.093).

12 A 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies

13 ity and mortality, which might be altered by rhGH therapy, were considered with specific attention to

14 rosiglitazone 4 mg twice daily, combination rhGH + rosiglitazone, or double placebo (control) for 12

15 0 micrograms/d), rhIGF-I (800 micrograms/d), rhGH+rhIGF-I (800 micrograms/d of each), or TPN alone fo

16 uscle strength significantly improved during rhGH treatment compared with placebo (P < 0.05).

17 ve procedures performed were measured during rhGH treatment and for 12 months after treatment was dis

18 Patients were randomized to receive either rhGH (0.05 mg/kg body weight) or placebo.

19 Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a random

20 six burned children were treated with either rhGH or rhGH plus propranolol.

21 Recent studies evaluating rhGH use in pediatric Crohn's disease have demonstrated

22 partial GH insensitivity should not exclude rhGH therapy; and safety concerns regarding rhGH therapy

23 Exogenous rhGH increased Ra FFA in children with large third-degre

24 (TPN) and treated with recombinant human GH (rhGH) (800 micrograms/d), rhIGF-I (800 micrograms/d), rh

25 in mortality could be shown for those given rhGH therapeutically versus their controls.

26 ts in the intensive care unit who were given rhGH has recently been reported in two large European tr

27 in elevated serum levels of recombinant hGH (rhGH) for more than one month.

28 enefits of recombinant human growth hormone (rhGH) alone or combined with glutamine in patients with

29 the use of recombinant human growth hormone (rhGH) as a potential therapy in achieving optimal growth

30 c doses of recombinant human growth hormone (rhGH) constitute another potential anabolic therapy in c

31 eated with recombinant human growth hormone (rhGH) for > or =7 days.

32 orption of recombinant human growth hormone (rhGH) from the gastrointestinal tract.

33 ability of recombinant human growth hormone (rhGH) has been studied by differential scanning calorime

34 ication of recombinant human growth hormone (rhGH) in serum has been developed using multistep sample

35 Recombinant human growth hormone (rhGH) reduces visceral adipose tissue (VAT) volume in HI

36 Recombinant human growth hormone (rhGH) therapy is used in the long-term treatment of chil

37 tration of recombinant human growth hormone (rhGH) to critically ill adults in an attempt to attenuat

38 safety of recombinant human growth hormone (rhGH) treatment in childhood have recently been raised;

39 tment with recombinant human growth hormone (rhGH), and to ascertain whether decreased free fatty aci

40 t low-dose recombinant human growth hormone (rhGH), given to children after a severe thermal injury,

41 strogen or recombinant human growth hormone (rhGH).

42 have used recombinant human growth hormone (rhGH; 0.2 mg/kg/day s.q.) to successfully treat 130 chil

43 pin (i.e., recombinant human growth hormone, rhGH) modified with the chelating agent S-2-(4-isothiocy

44 ed significantly in the rhGH arms (-17.5% in rhGH/rosiglitazone and -22.7% in rhGH) but not in the ro

45 (-17.5% in rhGH/rosiglitazone and -22.7% in rhGH) but not in the rosiglitazone alone (-2.5%) or cont

46 3) genotypes account for modest increases in rhGH effects in children; and 3) considerable unexplaine

47 onsiderations for using isotopically labeled rhGH as the internal standard are described.

48 of recombinant human growth hormone (0.15 mg rhGH/kg/day).

49 PN groups received 400 microg rhGH or equivolume 0.9% sodium chloride vehicle in a div

50 Neither PN, glutamine, nor rhGH had an effect on the increased liver protein synthe

51 gen, 1 patient had received estrogen but not rhGH, and 2 patients did not receive either therapy.

52 Administration of rhGH does not result in reduced liver glutamine levels o

53 Administration of rhGH for 1 year after burn was safe and improved recover

54 protein synthesis, and the administration of rhGH tended to further increase this effect.

55 ater than that induced by the same amount of rhGH administered by daily injections.

56 was used to demonstrate the oral delivery of rhGH in primates.

57 subjects were studied after 3 daily doses of rhGH.

58 Longer duration of rhGH treatment (HR, 2.08; 95% CI, 1.35-3.20) and total c

59 gnificantly modifying the lowering effect of rhGH on VAT.

60 e the potential additive anabolic effects of rhGH compared with IDPN and exercise on protein and ener

61 range, suggesting that beneficial effects of rhGH in hyperphagic patients might be achieved without g

62 The whole-body anabolic effects of rhGH observed during the prehemodialysis period persiste

63 o rhGH would abrogate the adverse effects of rhGH on insulin sensitivity (SI) and subcutaneous adipos

64 siglitazone abrogated the adverse effects of rhGH on insulin sensitivity and glucose tolerance while

65 In this study, we examined the effects of rhGH on plasma glutamine levels and on muscle and liver

66 We explored effects of rhGH on whole-body protein metabolism in patients with s

67 mine might ameliorate any adverse effects of rhGH.

68 te that the folding/unfolding equilibrium of rhGH involves a partially folded dimeric intermediate.

69 Group 1 received 1.4 mg of rhGH once daily plus placebo twice daily; group 2 receiv

70 d 5 mg of rhIGF-1 twice daily plus 1.4 mg of rhGH once daily; and group 4 received placebo three time

71 ls which questions the therapeutic safety of rhGH.

72 , temperature, and chaotrope on unfolding of rhGH documented that under conditions used for optimal h

73 ents or in the literature between the use of rhGH and the development of pilomatricomas.

74 f the GHR(fl-d3) and GHR(d3-d3) genotypes on rhGH therapy response and used a recently established Ba

75 A (P = 0.02); by pair-wise comparisons, only rhGH (decreasing SI; P = 0.03) differed significantly fr

76 ed children were treated with either rhGH or rhGH plus propranolol.

77 tween plasma GSH and TNF-alpha levels in our rhGH-supplemented trauma patients.

78 x min(-1) when the patients did not receive rhGH and -0.39 +/- 0.04 mg x kg fat-free mass(-1) x min(

79 ass(-1) x min(-1) when the patients received rhGH, a 22% improvement in prehemodialysis whole-body pr

80 of propranolol to burned children receiving rhGH is safe, has salutary cardiovascular effects, decre

81 t mass had decreased in the groups receiving rhGH, rhIGF-1, or both.

82 rhGH therapy; and safety concerns regarding rhGH therapy, particularly related to HCM and the risk o

83 artificial membrane (IAM) column, and serum rhGH concentrations following oral or colonic dosing in

84 There was no significant rhGH x rosiglitazone interaction for any body compositio

85 Data indicate that rhGH used in the treatment of children who were severely

86 Recent evidence suggests that rhGH therapy is effective in improving short-term linear

87 GH, were also elevated for four weeks by the rhGH containing microspheres to a level greater than tha

88 (1-way ANCOVA P = 0.004), increasing in the rhGH arm relative to control.

89 VAT decreased significantly in the rhGH arms (-17.5% in rhGH/rosiglitazone and -22.7% in rh

90 (HCM); importance of monitoring adherence to rhGH therapy; acknowledgment that partial GH insensitivi

91 No patient deaths were attributed to rhGH in autopsies reviewed by observers blinded to treat

92 ty and insulin resistance were randomized to rhGH 3 mg daily, rosiglitazone 4 mg twice daily, combina

93 imed to determine if adding rosiglitazone to rhGH would abrogate the adverse effects of rhGH on insul

94 less during the prehemodialysis period when rhGH was administered (-18 +/- 23 compared with -71 +/-

95 With rhGH administration, leucine release from protein breakd

96 With rhGH, the intestinal absorption of leucine and glutamine

97 No side effects with rhGH were observed.

98 ture except in the saline and glutamine with rhGH animals.

99 tive procedures was significantly lower with rhGH (P < 0.05).

100 lower in animals receiving standard PN with rhGH vs. saline alone.

101 saline and those receiving standard PN with rhGH.

102 Supplementation with rhGH enhanced GSH (180%), and TNF (65%) with no changes

103 7, after which no patients were treated with rhGH (n = 31).

104 matricomas, 5 patients had been treated with rhGH but not estrogen, 1 patient had received estrogen b

105 cohort study included patients treated with rhGH during childhood from January 1, 1985, to December

106 Included patients were treated with rhGH owing to isolated growth hormone deficiency (GHD),

107 Treatment with rhGH during childhood and adolescence (aged 0-18 years).

108 In this cohort study, treatment with rhGH during childhood due to GHD, SGA, or ISS was associ